Root, Inc. Class A Common Stock logo

Root, Inc. Class A Common Stock (ROOT)

Market Closed
15 Dec, 20:00
NASDAQ (NGS) NASDAQ (NGS)
$
81. 13
+0.11
+0.14%
$
1.11B Market Cap
- P/E Ratio
0% Div Yield
133,080 Volume
-11.53 Eps
$ 81.02
Previous Close
Day Range
80.24 82.4
Year Range
68.08 181.14
Want to track ROOT and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 71 days
Undercovered Dozen: Root, Marqeta, Caesars Entertainment, Rumble, Pubmatic +

Undercovered Dozen: Root, Marqeta, Caesars Entertainment, Rumble, Pubmatic +

In this article, we share 12 ideas published last week focused on stocks with less coverage on Seeking Alpha. Ideas this week include two new publicly traded notes, a satellite company, a card-issuer and processor, a PC insurance company, and more. One article highlighted is analyst Jussi Askola's current "favorite dividend pick".

Seekingalpha | 1 year ago
Root, Inc. (ROOT) Reports Q2 Loss, Tops Revenue Estimates

Root, Inc. (ROOT) Reports Q2 Loss, Tops Revenue Estimates

Root, Inc. (ROOT) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $1.74. This compares to loss of $2.55 per share a year ago.

Zacks | 1 year ago
Root, Inc. (ROOT) Q2 2024 Earnings Call Transcript

Root, Inc. (ROOT) Q2 2024 Earnings Call Transcript

Root, Inc. (NASDAQ:ROOT ) Q2 2024 Earnings Conference Call August 7, 2024 5:00 PM ET Company Participants Matt LaMalva - Head, IR Alex Timm - Co-Founder & CEO Megan Binkley - CFO Conference Call Participants Tommy McJoynt - KBW Yaron Kinar - Jefferies Elyse Greenspan - Wells Fargo Michael Ward - Citi Operator Greetings, and welcome to Root, Inc. Second Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.

Seekingalpha | 1 year ago
Regeneron: Expanded Product Base Taking Root, More Is Certainly On The Way

Regeneron: Expanded Product Base Taking Root, More Is Certainly On The Way

Regeneron is a powerhouse in drug discovery with a promising pipeline and innovative treatments. Revenues are stable with flagship drugs like Eylea providing a revenue cushion and Dupixent driving growth. The next-generation drugs in oncology and obesity are the next potential wave of growth, with even more exciting treatments following them.

Seekingalpha | 1 year ago
Is Root (ROOT) Outperforming Other Finance Stocks This Year?

Is Root (ROOT) Outperforming Other Finance Stocks This Year?

Here is how Root, Inc. (ROOT) and Popular (BPOP) have performed compared to their sector so far this year.

Zacks | 1 year ago
Root, Inc. (ROOT) Recently Broke Out Above the 20-Day Moving Average

Root, Inc. (ROOT) Recently Broke Out Above the 20-Day Moving Average

Root, Inc. (ROOT) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, ROOT broke through the 20-day moving average, which suggests a short-term bullish trend.

Zacks | 1 year ago
Root, Inc. (ROOT) Is Up 10.98% in One Week: What You Should Know

Root, Inc. (ROOT) Is Up 10.98% in One Week: What You Should Know

Does Root, Inc. (ROOT) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks | 1 year ago
Are You Looking for a Top Momentum Pick? Why Root, Inc. (ROOT) is a Great Choice

Are You Looking for a Top Momentum Pick? Why Root, Inc. (ROOT) is a Great Choice

Does Root, Inc. (ROOT) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks | 1 year ago
Root, Inc. (ROOT) Recently Broke Out Above the 20-Day Moving Average

Root, Inc. (ROOT) Recently Broke Out Above the 20-Day Moving Average

From a technical perspective, Root, Inc. (ROOT) is looking like an interesting pick, as it just reached a key level of support. ROOT recently overtook the 20-day moving average, and this suggests a short-term bullish trend.

Zacks | 1 year ago
Is Most-Watched Stock Root, Inc. (ROOT) Worth Betting on Now?

Is Most-Watched Stock Root, Inc. (ROOT) Worth Betting on Now?

Root (ROOT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Zacks | 1 year ago